Nessan Bermingham

Nessan is an Operating Partner at Khosla Ventures focused on life science companies with an emphasis on nucleic acid editing, novel delivery systems, gene and cell therapy, novel target identification and data analytics for drug discovery and development.

Having founded multiple companies in the life sciences realm, Nessan is a serial biotech entrepreneur and investor. Most notable among his companies are Intellia Therapeutics, a top-10 biotech startup in 2014, Triplet Therapeutics, and Korro Bio. At Intellia, Nessan served as president and CEO from inception through 2017, leading the company from concept through partner deals, multiple financing rounds and an IPO prior to its second anniversary.

Nessan also held investment roles at Atlas Venture and Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. He is currently the executive chair at Everyone Medicines, Korro Bio and Stylus Biomedicine. He also currently sits on the board of Deep Genomics, Liberate Bio, Ochre Bio and Focal Medical and is a board observer with CHARM Therapeutics and Eligo Bioscience.

Previously he was a member of the equity research team at UBS, an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London, and was a Howard Hughes Associate Fellow at Baylor College of Medicine.

  • 6
    Biotech companies founded
  • 155
    Miles run in self-supported ultra marathon
  • 49
    Age at which he got his motorbike license; aspires to ride in the Dakar race
Human After All
The Leading Strand
Deliver, but not to the liver: Liberate Bio developing targeted nucleic acid delivery technologies
Between the Biotech Waves
Apple Podcasts